StockNews.com upgraded shares of Amarin (NASDAQ:AMRN – Free Report) from a sell rating to a hold rating in a report published on Friday.
Amarin Stock Performance
Shares of AMRN opened at $0.53 on Friday. Amarin has a 52 week low of $0.43 and a 52 week high of $1.11. The stock has a market capitalization of $217.66 million, a price-to-earnings ratio of -5.89 and a beta of 1.82. The stock has a fifty day moving average of $0.55 and a 200-day moving average of $0.56.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of AMRN. Arkfeld Wealth Strategies L.L.C. lifted its stake in shares of Amarin by 52.6% in the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 20,000 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of Amarin in the 4th quarter valued at $36,000. Generation Capital Management LLC acquired a new stake in Amarin in the fourth quarter valued at $50,000. Stonepine Capital Management LLC bought a new position in Amarin during the 4th quarter worth $55,000. Finally, Kornitzer Capital Management Inc. KS raised its position in Amarin by 80.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 42,700 shares during the last quarter. 22.25% of the stock is currently owned by institutional investors.
About Amarin
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
See Also
- Five stocks we like better than Amarin
- Market Cap Calculator: How to Calculate Market Cap
- Is Myers Industries Poised for a Breakout?
- Upcoming IPO Stock Lockup Period, Explained
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- What Are the FAANG Stocks and Are They Good Investments?
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
